(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are NYRSTAR, NORTHERN DRILLING, and BERGENBIO.

Financial Asset	Price	Change	Updated (EST)
NYRSTAR (NYR.BR)	0.08	21.14%	2024-02-07 12:20:55
NORTHERN DRILLING (NODL.OL)	0.53	17.15%	2024-02-07 12:41:35
BERGENBIO (BGBIO.OL)	0.30	12.18%	2024-02-07 12:25:02
CROSSWOOD (CROS.PA)	8.45	7.64%	2024-02-07 13:01:55
NORDIC SEMICONDUC (NOD.OL)	86.32	6.83%	2024-02-07 12:41:29
CLARANOVA (CLA.PA)	2.52	6.33%	2024-02-07 13:01:13
LNA SANTE (LNA.PA)	20.85	5.84%	2024-02-07 13:05:45
ZALARIS (ZAL.OL)	49.00	5.38%	2024-02-07 12:44:29
BELIEVE (BLV.PA)	12.00	5.26%	2024-02-07 13:00:15
NYXOAH (NYXH.BR)	9.20	5.02%	2024-02-07 12:20:58

The three biggest losers today are MITHRA, PIERRE VAC BSA ACT, and GROUPE JAJ.

Financial Asset	Price	Change	Updated (EST)
MITHRA (MITRA.BR)	0.54	-24.44%	2024-02-07 12:20:44
PIERRE VAC BSA ACT (VACBS.PA)	0.09	-20%	2024-02-07 13:21:32
GROUPE JAJ (GJAJ.PA)	1.21	-15.97%	2024-02-07 13:04:25
GENSIGHT BIOLOGICS (SIGHT.PA)	0.33	-14.29%	2024-02-07 13:04:13
FERMENTALG (FALG.PA)	0.76	-12.34%	2024-02-07 13:03:22
UNIFIEDPOST GROUP (UPG.BR)	3.10	-10.79%	2024-02-07 12:21:56
CFI (CFI.PA)	0.54	-10%	2024-02-07 13:01:02
MYHOTELMATCH (MHM.PA)	0.85	-9.56%	2024-02-07 13:20:33
SEQUANA MEDICAL (SEQUA.BR)	3.65	-8.75%	2024-02-07 12:21:25
HYDROGENPRO (HYPRO.OL)	12.78	-7.93%	2024-02-07 12:40:29

Winners today

1. NYRSTAR (NYR.BR)

21.14% Price Change

Nyrstar NV does not have significant operations. Previously, it was engaged in the mining, smelting, and producing of zinc, lead, and other base and precious metals primarily in Europe, Australia, Canada, and the United States. Nyrstar NV was founded in 2007 and is based in Balen, Belgium.

BEL 20 ended the session with NYRSTAR rising 21.14% to €0.08 on Wednesday, following the last session’s downward trend. BEL 20 rose 0.15% to €3,625.95, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-0.01.

More news about NYRSTAR.

2. NORTHERN DRILLING (NODL.OL)

17.15% Price Change

Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING rising 17.15% to €0.53 on Wednesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI dropped 2.05% to €1,247.17, following the last session’s upward trend on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-5.95.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.

Volume

Today’s last reported volume for NORTHERN DRILLING is 1209610 which is 63.12% below its average volume of 3280010.

Yearly Top and Bottom Value

NORTHERN DRILLING’s stock is valued at kr0.53 at 21:40 EST, way below its 52-week high of kr34.90 and way higher than its 52-week low of kr0.31.

Volatility

NORTHERN DRILLING’s last week, last month’s, and last quarter’s current intraday variation average was a positive 5.94%, a negative 1.77%, and a positive 12.02%.

NORTHERN DRILLING’s highest amplitude of average volatility was 11.62% (last week), 5.84% (last month), and 12.02% (last quarter).

More news about NORTHERN DRILLING.

3. BERGENBIO (BGBIO.OL)

12.18% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO rising 12.18% to €0.30 on Wednesday while Oslo Børs Benchmark Index_GI slid 2.05% to €1,247.17.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-0.55.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.

Volatility

BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.14%, a negative 0.92%, and a positive 4.53%.

BERGENBIO’s highest amplitude of average volatility was 1.46% (last week), 3.66% (last month), and 4.53% (last quarter).

Yearly Top and Bottom Value

BERGENBIO’s stock is valued at kr0.30 at 21:40 EST, way below its 52-week high of kr13.03 and way higher than its 52-week low of kr0.08.

Volume

Today’s last reported volume for BERGENBIO is 80882400 which is 29.03% above its average volume of 62683300.

More news about BERGENBIO.

4. CROSSWOOD (CROS.PA)

7.64% Price Change

Crosswood SA engages in real estate activity in France. Its property portfolio includes shops and offices, and housing properties. The company was formerly known as Desquenne et Giral. Crosswood SA was incorporated in 1935 and is based in Paris, France. Crosswood SA operates as a subsidiary of Compagnie Financiere De Broceliande.

CAC 40 ended the session with CROSSWOOD rising 7.64% to €8.45 on Wednesday while CAC 40 slid 0.36% to €7,611.26.

Earnings Per Share

As for profitability, CROSSWOOD has a trailing twelve months EPS of €-0.11.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.48%.

Volume

Today’s last reported volume for CROSSWOOD is 1 which is 96.29% below its average volume of 27.

Yearly Top and Bottom Value

CROSSWOOD’s stock is valued at €8.45 at 21:40 EST, way below its 52-week high of €17.50 and way higher than its 52-week low of €6.65.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 6, 2023, the estimated forward annual dividend rate is 0.11 and the estimated forward annual dividend yield is 1.31%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.8%, now sitting on 1.07M for the twelve trailing months.

More news about CROSSWOOD.

5. NORDIC SEMICONDUC (NOD.OL)

6.83% Price Change

Nordic Semiconductor ASA, a fabless semiconductor company, designs, sells, and delivers integrated circuits (ICs) and related products and services for use in short- and long- range wireless applications in Europe, the Americas, and the Asia/Pacific. The company offers bluetooth and multiprotocol Systems-on-Chip (SoCs) that provides short-range connectivity; and Systems-in-Package (SiPs), which offers connectivity on long-range LTE-M and NB-IoT cellular networks. It also provides nRF9160 SiP low power cellular IoT device, nRF Cloud solution, nRF Connect software development kit, and third-party cellular modules; DECT NR+, a non-cellular radio standard; nRF7002 Wi-Fi companion ICs; and nRF52840 and nRF5340 multiprotocol SoCs. In addition, the company offers Bluetooth mesh; Bluetooth direction finding solution; Bluetooth Low Energy SoCs; Bluetooth LE audio products; Matter, a Connected Home over IP solution; Thread, an IP-based wireless networking protocol solution; Zigbee products; ANT solutions, including wireless multiprotocol SoCs supporting the ANT wireless protocol; pre-certified development modules and modems; and range extenders. Further, it provides built-in power management on SoCs and dedicated power management ICs comprising nPM1100 PMIC, nPM1300 PMIC, nPM6001 PMIC, nPM1100 EK, and Power Profiler Kit II; Device-to-nRF Cloud and Cloud-to-nRF Cloud solutions; and application specific integrated circuits and related consulting services. The company's products are used in various applications, such as automotive, beacon, computer peripherals, connected health, connected home, education, industrial automation, LED lighting, logistics and transport, retail and payment, sports and fitness, toys and gaming, virtual reality and augmented reality products, and wearables. Nordic Semiconductor ASA was founded in 1983 and is headquartered in Trondheim, Norway.

Oslo Børs Benchmark Index_GI ended the session with NORDIC SEMICONDUC jumping 6.83% to €86.32 on Wednesday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 2.05% to €1,247.17, following the last session’s upward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, NORDIC SEMICONDUC has a trailing twelve months EPS of kr2.82.

PE Ratio

NORDIC SEMICONDUC has a trailing twelve months price to earnings ratio of 30.61. Meaning, the purchaser of the share is investing kr30.61 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.88%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 33.2%, now sitting on 626.05M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NORDIC SEMICONDUC’s stock is considered to be overbought (>=80).

More news about NORDIC SEMICONDUC.

6. CLARANOVA (CLA.PA)

6.33% Price Change

Claranova SE, a technology company, engages in personalized e-commerce, software publishing, and internet of things (IoT) management in France, the United States, the United Kingdom, Germany, other European countries, and internationally. It operates in three segments: PlanetArt, Avanquest, and myDevices. The PlanetArt segment offers photos, frames, personalized books, and FreePrints mobile applications. The Avanquest segment provides antivirus, ad blocker, cleaning, and optimization tools under the Adaware brand; document management tools under the SodaPDF brand; and photo editor software and applications developed under the inPixio brand. The myDevices segment offers IoT solutions. Claranova SE was incorporated in 1984 and is headquartered in Courbevoie, France.

CAC 40 ended the session with CLARANOVA jumping 6.33% to €2.52 on Wednesday while CAC 40 fell 0.36% to €7,611.26.

Earnings Per Share

As for profitability, CLARANOVA has a trailing twelve months EPS of €-0.23.

Moving Average

CLARANOVA’s value is way above its 50-day moving average of €1.96 and way higher than its 200-day moving average of €1.75.

Volume

Today’s last reported volume for CLARANOVA is 525227 which is 251.96% above its average volume of 149227.

Volatility

CLARANOVA’s last week, last month’s, and last quarter’s current intraday variation average was 1.39%, 0.64%, and 3.01%.

CLARANOVA’s highest amplitude of average volatility was 3.72% (last week), 2.65% (last month), and 3.01% (last quarter).

More news about CLARANOVA.

7. LNA SANTE (LNA.PA)

5.84% Price Change

LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.

CAC 40 ended the session with LNA SANTE jumping 5.84% to €20.85 on Wednesday, after two sequential sessions in a row of losses. CAC 40 fell 0.36% to €7,611.26, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.

PE Ratio

LNA SANTE has a trailing twelve months price to earnings ratio of 9.14. Meaning, the purchaser of the share is investing €9.14 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.

More news about LNA SANTE.

8. ZALARIS (ZAL.OL)

5.38% Price Change

Zalaris ASA provides full-service outsourced personnel and payroll services. The company operates in two segments, Managed Services and Professional Services. It offers a range of payroll and human resource (HR) outsourcing services, including payroll processing, time and attendance, and travel expenses, as well as cloud-based HR functionality services, such as talent management, digital personnel archive, HR analytics, mobile solutions, etc. The company also engages in the implementation of SAP HCM, and Payroll and SuccessFactors, as well as provides consulting services. It serves bank, insurance, finance, health and life science, infrastructure and transportation, IT, telecom, offshore and energy, product, retail, and service industries, as well as public services and other institutions. The company has operations in Norway, Sweden, Denmark, Finland, Germany, Latvia, the United Kingdom, Poland, and internationally. The company was formerly known as Zalaris HR Services AS and changed its name to Zalaris ASA in May 2014. Zalaris ASA was incorporated in 2000 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ZALARIS rising 5.38% to €49.00 on Wednesday, after four sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI fell 2.05% to €1,247.17, following the last session’s upward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, ZALARIS has a trailing twelve months EPS of kr-1.13.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.65%.

More news about ZALARIS.

9. BELIEVE (BLV.PA)

5.26% Price Change

Believe S.A. provides music distribution and marketing services for artists and labels worldwide. The company's physical and digital distribution services include a range of digital music services and video streaming, as well as a network of physical distribution partners. It also provides brand partnership, video, synchronization, music publishing and additional services. Believe S.A. was incorporated in 2005 and is headquartered in Paris, France.

CAC 40 ended the session with BELIEVE jumping 5.26% to €12.00 on Wednesday while CAC 40 dropped 0.36% to €7,611.26.

Earnings Per Share

As for profitability, BELIEVE has a trailing twelve months EPS of €-0.22.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.27%.

More news about BELIEVE.

10. NYXOAH (NYXH.BR)

5.02% Price Change

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with NYXOAH rising 5.02% to €9.20 on Wednesday while BEL 20 rose 0.15% to €3,625.95.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.68.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.76%.

Yearly Top and Bottom Value

NYXOAH’s stock is valued at €9.20 at 21:40 EST, way under its 52-week high of €12.60 and way above its 52-week low of €3.79.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 25.5% and 17.4%, respectively.

More news about NYXOAH.

Losers Today

1. MITHRA (MITRA.BR)

-24.44% Price Change

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

BEL 20 ended the session with MITHRA dropping 24.44% to €0.54 on Wednesday while BEL 20 rose 0.15% to €3,625.95.

Earnings Per Share

As for profitability, MITHRA has a trailing twelve months EPS of €-1.41.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -575.59%.

Volume

Today’s last reported volume for MITHRA is 1093980 which is 605.53% above its average volume of 155057.

More news about MITHRA.

2. PIERRE VAC BSA ACT (VACBS.PA)

-20% Price Change

CAC 40 ended the session with PIERRE VAC BSA ACT falling 20% to €0.09 on Wednesday, after consecutive sessions in a row of losses. CAC 40 dropped 0.36% to €7,611.26, following the last session’s upward trend on what was a somewhat down trend exchanging session today.

Yearly Top and Bottom Value

PIERRE VAC BSA ACT’s stock is valued at €0.09 at 21:40 EST, way under its 52-week low of €0.11.

More news about PIERRE VAC BSA ACT.

3. GROUPE JAJ (GJAJ.PA)

-15.97% Price Change

Groupe JAJ distributes clothing products. It offers clothing products of the SCHOTT brand. The company was formerly known as JAJ Distribution. The company is headquartered in Montreuil, France.

CAC 40 ended the session with GROUPE JAJ falling 15.97% to €1.21 on Wednesday while CAC 40 dropped 0.36% to €7,611.26.

Earnings Per Share

As for profitability, GROUPE JAJ has a trailing twelve months EPS of €0.15.

PE Ratio

GROUPE JAJ has a trailing twelve months price to earnings ratio of 8.07. Meaning, the purchaser of the share is investing €8.07 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 56.17%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Nov 15, 2005, the estimated forward annual dividend yield is 2.92%.

Volume

Today’s last reported volume for GROUPE JAJ is 10 which is 98.65% below its average volume of 741.

Revenue Growth

Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 21.14M for the twelve trailing months.

Yearly Top and Bottom Value

GROUPE JAJ’s stock is valued at €1.21 at 21:40 EST, under its 52-week low of €1.30.

More news about GROUPE JAJ.

4. GENSIGHT BIOLOGICS (SIGHT.PA)

-14.29% Price Change

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.

CAC 40 ended the session with GENSIGHT BIOLOGICS dropping 14.29% to €0.33 on Wednesday while CAC 40 dropped 0.36% to €7,611.26.

Earnings Per Share

As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.63.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENSIGHT BIOLOGICS’s stock is considered to be overbought (>=80).

Volatility

GENSIGHT BIOLOGICS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.12%, a negative 1.11%, and a positive 2.95%.

GENSIGHT BIOLOGICS’s highest amplitude of average volatility was 1.12% (last week), 2.25% (last month), and 2.95% (last quarter).

Volume

Today’s last reported volume for GENSIGHT BIOLOGICS is 307896 which is 150% above its average volume of 123154.

Moving Average

GENSIGHT BIOLOGICS’s worth is way under its 50-day moving average of €0.55 and way under its 200-day moving average of €1.40.

More news about GENSIGHT BIOLOGICS.

5. FERMENTALG (FALG.PA)

-12.34% Price Change

Fermentalg SA develops, produces, and sells active ingredients extracted from microalgae for the food, health, nutrition, and environment sectors in France and internationally. It offers DHA ORIGINS, a plant-based DHA oil; KALVEA PLUS, a nutritious algal protein concentrate dedicated to aquafeed applications; Everzure, an extract of natural acid stable blue color; BLUE ORIGINS AOX, an antioxidant and anti-inflammatory activities; BLUE ORIGIN, a natural color; and environmental and clean air solutions that captures CO2 in industries. The company was incorporated in 2009 and is headquartered in Libourne, France.

CAC 40 ended the session with FERMENTALG sliding 12.34% to €0.76 on Wednesday while CAC 40 dropped 0.36% to €7,611.26.

Earnings Per Share

As for profitability, FERMENTALG has a trailing twelve months EPS of €-0.24.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.52%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 55.4%, now sitting on 4.75M for the twelve trailing months.

Volume

Today’s last reported volume for FERMENTALG is 950016 which is 34.35% above its average volume of 707112.

Yearly Top and Bottom Value

FERMENTALG’s stock is valued at €0.76 at 21:40 EST, way below its 52-week high of €1.87 and way above its 52-week low of €0.21.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FERMENTALG’s stock is considered to be oversold (<=20).

More news about FERMENTALG.

6. UNIFIEDPOST GROUP (UPG.BR)

-10.79% Price Change

UnifiedPost Group SA, a fintech company, operates and develops a cloud-based platform for administrative and financial services in Belgium and internationally. Its platform allows connections between its customers, suppliers, customers, and other parties in the financial supply chain. The company offers a technology portfolio for document processing, identity management, payment services, and added value financial services, as well as engages in post and parcel optimization activities. It serves corporate and government customers; small and medium-sized enterprises; and agricultural, accounting, interim, and construction sectors. UnifiedPost Group SA was founded in 2001 and is headquartered in La Hulpe, Belgium.

BEL 20 ended the session with UNIFIEDPOST GROUP sliding 10.79% to €3.10 on Wednesday, after two consecutive sessions in a row of gains. BEL 20 jumped 0.15% to €3,625.95, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, UNIFIEDPOST GROUP has a trailing twelve months EPS of €-1.32.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.78%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, UNIFIEDPOST GROUP’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.6%, now sitting on 192.46M for the twelve trailing months.

Yearly Top and Bottom Value

UNIFIEDPOST GROUP’s stock is valued at €3.10 at 21:40 EST, way below its 52-week high of €4.73 and way higher than its 52-week low of €2.01.

Volume

Today’s last reported volume for UNIFIEDPOST GROUP is 15698 which is 5.1% above its average volume of 14936.

More news about UNIFIEDPOST GROUP.

7. CFI (CFI.PA)

-10% Price Change

CFI-Compagnie Foncière Internationale, a real estate investment company, engages in leasing land and other property assets. The company was formerly known as Didot-Bottin and changed its name on December 9, 2008. As of December 31, 2009, its real estate portfolio comprised 12 assets located in France. CFI-Compagnie Foncière Internationale was founded in 1796 and is based in Paris, France.

CAC 40 ended the session with CFI dropping 10% to €0.54 on Wednesday, after five sequential sessions in a row of losses. CAC 40 dropped 0.36% to €7,611.26, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, CFI has a trailing twelve months EPS of €-0.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -866.67%.

More news about CFI.

8. MYHOTELMATCH (MHM.PA)

-9.56% Price Change

MyHotelMatch S.A. engages in the development of an online hotel reservation platform based on Artificial Intelligence (AI). It operates as an online travel agency based on the principle of online dating. MyHotelMatch S.A. was incorporated in 2010 and is headquartered in Biot, France.

CAC 40 ended the session with MYHOTELMATCH sliding 9.56% to €0.85 on Wednesday while CAC 40 slid 0.36% to €7,611.26.

Earnings Per Share

As for profitability, MYHOTELMATCH has a trailing twelve months EPS of €-1.5.

Moving Average

MYHOTELMATCH’s worth is below its 50-day moving average of €0.89 and way below its 200-day moving average of €1.65.

Volatility

MYHOTELMATCH’s last week, last month’s, and last quarter’s current intraday variation average was 8.51%, 0.35%, and 3.30%.

MYHOTELMATCH’s highest amplitude of average volatility was 13.82% (last week), 5.29% (last month), and 3.30% (last quarter).

Yearly Top and Bottom Value

MYHOTELMATCH’s stock is valued at €0.85 at 21:40 EST, way under its 52-week high of €3.88 and way above its 52-week low of €0.64.

Volume

Today’s last reported volume for MYHOTELMATCH is 13424 which is 45.86% above its average volume of 9203.

More news about MYHOTELMATCH.

9. SEQUANA MEDICAL (SEQUA.BR)

-8.75% Price Change

Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

BEL 20 ended the session with SEQUANA MEDICAL sliding 8.75% to €3.65 on Wednesday, following the last session’s upward trend. BEL 20 rose 0.15% to €3,625.95, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.32.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -690.43%.

More news about SEQUANA MEDICAL.

10. HYDROGENPRO (HYPRO.OL)

-7.93% Price Change

HydrogenPro ASA designs and supplies customized hydrogen plants. It provides high-pressure alkaline electrolysers. The company was incorporated in 2013 and is headquartered in Porsgrunn, Norway.

Oslo Børs Benchmark Index_GI ended the session with HYDROGENPRO sliding 7.93% to €12.78 on Wednesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI slid 2.05% to €1,247.17, following the last session’s upward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, HYDROGENPRO has a trailing twelve months EPS of kr-0.95.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.28%.

Volume

Today’s last reported volume for HYDROGENPRO is 139569 which is 37.5% above its average volume of 101498.

More news about HYDROGENPRO.

Stay up to date with our winners and losers daily report